In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • Stereotactic Radiosurgery for the Management of A Randomized Trial of Unruptured Brain Arteriovenous Malformations (ARUBA)-Eligible Patients: An International Multicenter Study

    Final Number:
    111

    Authors:
    D Ding; RM Starke; H Kano; D Mathieu; PP Huang; D Kondziolka; CE Feliciano; R Rodriguez-Mercado; L Almodovar; IS Grills; D Silva; MA Abbassy; S Missios; GH Barnett; LD Lunsford; JP Sheehan

    Study Design:
    Other

    Subject Category:
    Vascular Malformations

    Meeting: AANS/CNS Cerebrovascular Section 2017 Annual Meeting

    Introduction: The benefit of intervention for patients with unruptured intracranial arteriovenous malformations (AVM) was challenged by results demonstrating superior clinical outcomes with conservative management from A Randomized Trial of Unruptured Brain AVMs (ARUBA). The aim of this multicenter, retrospective cohort study is to analyze the outcomes of stereotactic radiosurgery for ARUBA-eligible patients.

    Methods: We combined AVM radiosurgery outcome data from seven institutions participating in the International Gamma Knife Research Foundation (IGKRF). Patients with =12 months of follow-up were screened for ARUBA eligibility criteria. Favorable outcome was defined as AVM obliteration, no post-radiosurgery hemorrhage, and no permanently symptomatic radiation-induced changes (RIC). Adverse neurological outcome was defined as any new or worsening neurological symptoms or death.

    Results: The ARUBA-eligible cohort comprised 509 patients (mean age 40 years). The Spetzler-Martin grade was I-II in 46% and III-IV in 54%. The mean radiosurgical margin dose was 22 Gy and follow-up was 86 months. AVM obliteration was achieved in 75%. The post-radiosurgery hemorrhage rate during the latency period was 0.9%/year. Symptomatic and permanent RIC occurred in 11% and 3%, respectively. The rates of favorable outcome, adverse neurological outcome, permanent neurological morbidity, and mortality were 70%, 13%, 5%, and 4%, respectively.

    Conclusions: Radiosurgery may provide durable clinical benefit in some ARUBA-eligible patients. Based on the natural history of untreated, unruptured AVMs in the medical arm of ARUBA, we estimate that a follow-up duration of 15-20 years is necessary to realize a potential benefit of radiosurgical intervention over conservative management in unruptured AVM patients.

    Patient Care: The management of unruptured AVMs is a controversial topic. The initial results from A Randomized Trial of Unruptured Brain AVMs (ARUBA) showed significantly worse outcomes after intervention compared to conservative management for unruptured AVM patients. However, ARUBA was appropriately criticized for a number of weaknesses. In this retrospective, multicenter analysis, we attempt to address some of the shortcomings of ARUBA and show that, for appropriately selected ARUBA-eligible patients, treatment with radiosurgery may provide a long-term benefit over conservative management.

    Learning Objectives: By the conclusion of this session, participants should be able to 1) Describe the importance of stereotactic radiosurgery in the management of ARUBA-eligible patients, 2) Discuss, in small groups the outcomes after radiosurgery in patients who were eligible for A Randomized Trial of Unruptured Brain AVMs (ARUBA), and 3) Identify an effective treatment for unruptured brain arteriovenous malformations.

    References: 1. Ding D, Starke RM, Kano H, et al. Radiosurgery for Cerebral Arteriovenous Malformations in A Randomized Trial of Unruptured Brain Arteriovenous Malformations (ARUBA)-Eligible Patients: A Multicenter Study. Stroke. Feb 2016;47(2):342-349.

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy